ETA/ETB receptor blocker, bosentan, were investigated after 6 months of follow-up. MT was measured by cadmium-heme assay. Metals were measured by atomic absorption spectrometer. ET-1 mRNA was analyzed by reverse transcriptase–polymerase chain reaction (RT-PCR) technique. Hepatic and renal ET-1 mRNA was increased in diabetic rats as compared to control rats, along with an increase in both hepatic and renal MT proteins. The increased hepatic MT protein level was associated with decreases in hepatic Cu and Fe, whereas increased renal MT was associated with increases in renal Cu and Fe accumulation. Zn levels were unaltered in both organs in diabetic rats. Bosentan treatment partially prevented the increase in MT levels in both liver and kidney, along with reduced serum creatinine and increased urinary creatinine levels. Further bosentan treatment corrected the increased Cu and Fe levels in the kidney in diabetic rats, but reduced hepatic Cu and Fe levels. No significant effects of bosentan treatment on nondiabetic rats were observed. The data suggest that the possible effects of ET antagonism in diabetes may be mediated via changes in MT and trace metals."> Endothelin-1-Mediated改变金属硫蛋白和微量金属的慢性糖尿病大鼠的肝脏和肾脏 - raybet雷竞app,雷竞技官网下载,雷电竞下载苹果

糖尿病研究期刊》的研究

//文章

在这一页上

文摘版权

开放获取

体积 3 |文章的ID 712125年 | https://doi.org/10.1080/15604280214281

陆Cai,沙里陈时,特里埃文斯,m .乔治Cherian Subrata Chakrabarti, ”Endothelin-1-Mediated改变金属硫蛋白和微量金属的慢性糖尿病大鼠的肝脏和肾脏”,糖尿病研究期刊》的研究, 卷。3, 文章的ID712125年, 6 页面, 2002年。 https://doi.org/10.1080/15604280214281

Endothelin-1-Mediated改变金属硫蛋白和微量金属的慢性糖尿病大鼠的肝脏和肾脏

陆蔡,¹ 沙里陈,¹ 特里埃文斯,¹ 乔治·m·契连,¹ 和 Subrata Chakrabarti¹

¹西安大略大学病理学系,牙科科学大楼,伦敦、安大略省N6A 5 c1,加拿大

收到了 2002年3月04

接受 2002年5月23日

文摘

在目前的研究中,所扮演的角色endothelin-1 (ET-1)改变肝和肾的金属硫蛋白(MT)和微量金属(锌、铜、铁)研究了在链脲霉素(STZ)诱导的糖尿病大鼠。糖尿病大鼠、年龄和sex-matched控制,以及控制和双重糖尿病动物等一个 / 等 B 受体阻断剂,应用波生坦,经过6个月的随访调查。太被cadmium-heme试验测量。金属是由原子吸收光谱仪测量。ET-1 mRNA分析了反向transcriptase-polymerase连锁反应(rt - pcr)技术。肝和肾ET-1 mRNA在糖尿病大鼠相比增加控制老鼠,以及增加在肝和肾太蛋白质。增加肝脏MT蛋白水平与肝铜和铁的减少,而增加肾太与肾铜和铁的增加积累。锌含量不变的在这两个器官在糖尿病大鼠。应用波生坦治疗部分阻止MT含量的增加肝脏和肾脏,降低血清肌酐和尿肌酐水平增加。应用波生坦进一步纠正增加铜和铁水平在糖尿病大鼠肾脏,但肝铜和铁水平降低。应用波生坦没有显著的影响在非糖尿病的老鼠。 The data suggest that the possible effects of ET antagonism in diabetes may be mediated via changes in MT and trace metals.

版权

版权©2002 Hindawi出版公司。这是一个开放的分布式下文章知识共享归属许可,它允许无限制的使用、分配和复制在任何媒介,提供最初的工作是正确引用。

PDF

下载引用

引用

订单打印副本订单

的观点202年

下载515年

引用

文章奖:2020年杰出的研究贡献,选择由我们的首席编辑。获奖的文章阅读。